217 related articles for article (PubMed ID: 28951410)
1. Cost-effectiveness of milk powder fortified with potassium to decrease blood pressure and prevent cardiovascular events among the adult population in China: a Markov model.
Dainelli L; Xu T; Li M; Zimmermann D; Fang H; Wu Y; Detzel P
BMJ Open; 2017 Sep; 7(9):e017136. PubMed ID: 28951410
[TBL] [Abstract][Full Text] [Related]
2. Milk Powder Fortified with Potassium and Phytosterols to Decrease the Risk of Cardiovascular Events among the Adult Population in Malaysia: A Cost-Effectiveness Analysis.
Gandola AE; Dainelli L; Zimmermann D; Dahlui M; Detzel P
Nutrients; 2019 May; 11(6):. PubMed ID: 31151244
[TBL] [Abstract][Full Text] [Related]
3. Public health impact and economic evaluation of vitamin D-fortified dairy products for fracture prevention in France.
Hiligsmann M; Burlet N; Fardellone P; Al-Daghri N; Reginster JY
Osteoporos Int; 2017 Mar; 28(3):833-840. PubMed ID: 27757506
[TBL] [Abstract][Full Text] [Related]
4. The Cost-Effectiveness of Low-Cost Essential Antihypertensive Medicines for Hypertension Control in China: A Modelling Study.
Gu D; He J; Coxson PG; Rasmussen PW; Huang C; Thanataveerat A; Tzong KY; Xiong J; Wang M; Zhao D; Goldman L; Moran AE
PLoS Med; 2015 Aug; 12(8):e1001860. PubMed ID: 26241895
[TBL] [Abstract][Full Text] [Related]
5. Estimation and Prediction of Avoidable Health Care Costs of Cardiovascular Diseases and Type 2 Diabetes Through Adequate Dairy Food Consumption: A Systematic Review and Micro Simulation Modeling Study.
Javanbakht M; Jamshidi AR; Baradaran HR; Mohammadi Z; Mashayekhi A; Shokraneh F; Rezai Hamami M; Yazdani Bakhsh R; Shabaninejad H; Delavari S; Tehrani A
Arch Iran Med; 2018 May; 21(5):213-222. PubMed ID: 29738265
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness of different screening strategies for primary prevention of cardiovascular diseases in a rural northern Chinese population].
Si YQ; Tang X; Zhang DD; He L; Cao Y; Wang JW; Li N; Liu JJ; Gao P; Hu YH
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Jun; 50(3):443-449. PubMed ID: 29930411
[TBL] [Abstract][Full Text] [Related]
8. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and public health benefit of secondary cardiovascular disease prevention from improved adherence using a polypill in the UK.
Becerra V; Gracia A; Desai K; Abogunrin S; Brand S; Chapman R; García Alonso F; Fuster V; Sanz G
BMJ Open; 2015 May; 5(5):e007111. PubMed ID: 25991449
[TBL] [Abstract][Full Text] [Related]
11. Cost and cost-effectiveness of a school-based education program to reduce salt intake in children and their families in China.
Li X; Jan S; Yan LL; Hayes A; Chu Y; Wang H; Feng X; Niu W; He FJ; Ma J; Han Y; MacGregor GA; Wu Y
PLoS One; 2017; 12(9):e0183033. PubMed ID: 28902880
[TBL] [Abstract][Full Text] [Related]
12. Long Term Cost-Effectiveness of a Systolic Blood Pressure Goal of <120 mmHg in Hypertensive Patients Without Diabetes Mellitus.
Almalki ZS; Iqbal MS; Alablan FM; Alenazi RK; Tasha AR; Daghar MF; Aldossary NM
Value Health Reg Issues; 2020 May; 21():157-163. PubMed ID: 31978689
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of 10-Year Risk Thresholds for Initiation of Statin Therapy for Primary Prevention of Cardiovascular Disease.
Pandya A; Sy S; Cho S; Weinstein MC; Gaziano TA
JAMA; 2015 Jul; 314(2):142-50. PubMed ID: 26172894
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of personalized supplementation with vitamin D-rich dairy products in the prevention of osteoporotic fractures.
Ethgen O; Hiligsmann M; Burlet N; Reginster JY
Osteoporos Int; 2016 Jan; 27(1):301-8. PubMed ID: 26395885
[TBL] [Abstract][Full Text] [Related]
15. The influence of absolute cardiovascular risk, patient utilities, and costs on the decision to treat hypertension: a Markov decision analysis.
Montgomery AA; Fahey T; Ben-Shlomo Y; Harding J
J Hypertens; 2003 Sep; 21(9):1753-9. PubMed ID: 12923409
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of intensive hypertension control in China.
Xie X; He T; Kang J; Siscovick DS; Li Y; Pagán JA
Prev Med; 2018 Jun; 111():110-114. PubMed ID: 29525577
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model.
Zomer E; Owen A; Magliano DJ; Liew D; Reid CM
BMJ; 2012 May; 344():e3657. PubMed ID: 22653982
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of initiation of antihypertensive therapy strategies for primary prevention of cardiovascular diseases in Chinese population: A decision-analytic Markov modelling study].
Zhou T; Liu Q; Zhang M; Liu X; Kang J; Shen P; Lin H; Tang X; Gao P
Beijing Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 56(3):441-447. PubMed ID: 38864129
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China.
Ning G; Yin Z; Li Y; Wang H; Yang W
Hum Vaccin Immunother; 2018 Jan; 14(1):36-44. PubMed ID: 29049002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
